Drug Trial Radar · NCT06536374
Folate Study in Men With Advanced Prostate Cancer
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
50
Planned (sponsor's estimate)
Start
Dec 2026
Primary completion
Dec 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- University of California, San DiegoAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 2, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The researchers hope to learn if Trimethoprim, 150mg taken daily for 3 months, is a safe and effective way to reduce folate levels at time of Androgen Deprivation Therapy (ADT) in men with advanced prostate cancer. This study will help find out what effects, good and/or bad, this drug has on people who take it and on its effect on the disease. The safety of this drug in humans has been tested in prior research studies; however, some side effects may not yet be known.
Conditions
- Prostate Cancer
Interventions
Trimethoprim TabletsDrug
Trimethoprim 150mg is administered once daily for 3 months
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety of TrimethoprimTime frame: From first dose of study therapy through 1 month after completion of study therapy.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of California, San Diego
La Jolla, California · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.